Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regeneron Pharmaceuticals, Inc.

http://www.regeneron.com

Latest From Regeneron Pharmaceuticals, Inc.

Keeping Track: Regeneron Ebola Antibody Cocktail Inmazeb Approved; Avenue Feels Pain From CRL; Scynexis Submits Oral Antifungal

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Approvals Drug Approval Standards

Regeneron's Inmazeb Approval For Ebola Paves The Way In COVID-19

The US FDA approved the first antibody cocktail for ebolavirus infection, supporting a supply contract with BARDA. The development experience informed Regeneron's work in COVID-19.

Infectious Diseases Approvals

Roche Strikes Reality Note For Production Of Regeneron-Partnered COVID-19 Antibody Cocktail

Roche Pharma CEO Bill Anderson is excited about the prospects for REGN-COV2 but with the company and Regeneron possibly producing two million doses per year by the end of Q1 2021, meeting demand worldwide will be an impossible task.

Coronavirus COVID-19 Manufacturing

Coronavirus Update: Trial Of Lilly's Antibody Is Next To Be Paused

NIH study of monoclonal antibody therapy in combination with Gilead's remdesivir paused for safety reasons.

Infectious Diseases Coronavirus COVID-19
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Regeneron Genetics Center LLC (RGC)
UsernamePublicRestriction

Register